These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26967759)

  • 21. Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins.
    Tan H; Su W; Zhang W; Wang P; Sattler M; Zou P
    Curr Pharm Des; 2018; 24(41):4932-4946. PubMed ID: 30727869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.
    Gao X; Ji JA; Veeravalli K; Wang YJ; Zhang T; Mcgreevy W; Zheng K; Kelley RF; Laird MW; Liu J; Cromwell M
    J Pharm Sci; 2015 Feb; 104(2):368-77. PubMed ID: 25175600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.
    Sesarman A; Vidarsson G; Sitaru C
    Cell Mol Life Sci; 2010 Aug; 67(15):2533-50. PubMed ID: 20217455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
    Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
    Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.
    Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA
    J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural characterization of a human Fc fragment engineered for extended serum half-life.
    Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
    Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants.
    Petersen SS; Kläning E; Ebbesen MF; Andersen B; Cameron J; Sørensen ES; Howard KA
    Mol Pharm; 2016 Feb; 13(2):677-82. PubMed ID: 26654692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-Based Design and Discovery of a Long-Acting Cocaine Hydrolase Mutant with Improved Binding Affinity to Neonatal Fc Receptor for Treatment of Cocaine Abuse.
    Zheng F; Chen X; Kim K; Zhang T; Huang H; Zhou S; Zhang J; Jin Z; Zhan CG
    AAPS J; 2020 Mar; 22(3):62. PubMed ID: 32189158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.
    Sockolosky JT; Szoka FC
    Adv Drug Deliv Rev; 2015 Aug; 91():109-24. PubMed ID: 25703189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn.
    Ying T; Wang Y; Feng Y; Prabakaran P; Gong R; Wang L; Crowder K; Dimitrov DS
    MAbs; 2015; 7(5):922-30. PubMed ID: 26179052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Humanized Mouse Model to Study Human Albumin and Albumin Conjugates Pharmacokinetics.
    Low BE; Wiles MV
    Methods Mol Biol; 2016; 1438():115-22. PubMed ID: 27150087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics.
    Cho SY; Han J; Cha SH; Yoon SI
    Biochem Biophys Res Commun; 2020 Jun; 526(4):941-946. PubMed ID: 32284170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.
    Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW
    Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FcRn: the neonatal Fc receptor comes of age.
    Roopenian DC; Akilesh S
    Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.
    Qiu Y; Lv W; Xu M; Xu Y
    J Control Release; 2016 May; 229():37-47. PubMed ID: 26988600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
    Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.
    Dumont JA; Bitonti AJ; Clark D; Evans S; Pickford M; Newman SP
    J Aerosol Med; 2005; 18(3):294-303. PubMed ID: 16181004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.